for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AcelRx Pharmaceuticals Inc

ACRX.OQ

Latest Trade

2.21USD

Change

0.01(+0.23%)

Volume

51,374

Today's Range

2.19

 - 

2.22

52 Week Range

2.00

 - 

5.05

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.20
Open
2.20
Volume
51,374
3M AVG Volume
17.90
Today's High
2.22
Today's Low
2.19
52 Week High
5.05
52 Week Low
2.00
Shares Out (MIL)
79.44
Market Cap (MIL)
174.76
Forward P/E
-2.92
Dividend (Yield %)
--

Latest Developments

More

Acelrx Pharma Reports Q2 Loss Per Share Of $0.16

Acelrx Added To The Russell 2000® And 3000® Indexes

Acelrx Pharma Inc Says May Offer And Sell Shares Of Common Stock Of Up To $46.6 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Industry

Biotechnology & Drugs

Contact Info

351 Galveston Dr

+1.650.2163500

http://www.acelrx.com

Executive Leadership

Adrian Adams

Independent Chairman of the Board

Vincent J. Angotti

Chief Executive Officer, Director

Pamela P. Palmer

Co-Founder, Director, Chief Medical Officer

Raffi M. Asadorian

Chief Financial Officer

Badri N. Dasu

Chief Engineering Officer

Key Stats

1.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.950

2017

-1.100

2018

-0.810

2019(E)

-0.753
Price To Earnings (TTM)
--
Price To Sales (TTM)
79.58
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-64.59
Return on Equity (TTM)
-56.86

Latest News

Latest News

FDA approves AcelRx Pharma's opioid pain drug

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move.

AcelRx Pharma's opioid pain drug gets U.S. FDA nod

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based pain treatment, a fast-acting pill.

AcelRx shares surge after FDA staff says opioid safe

AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

BRIEF-AcelRx Announces FDA Acceptance Of NDA For Dsuvia

* ACELRX PHARMACEUTICALS INC - DSUVIA PDUFA DATE SET FOR NOVEMBER 3, 2018

BRIEF-Three Arch's Shares Of AcelRx Stock Acquired In Transaction Led By Leerink Revelation Partners And Industry Ventures

* THREE ARCH'S SHARES OF ACELRX COMMON STOCK ACQUIRED IN A PRIVATE TRANSACTION LED BY LEERINK REVELATION PARTNERS AND INDUSTRY VENTURES

BRIEF-AcelRx Pharmaceuticals Reports Q1 Loss Per Share $0.23

* ACELRX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Acelrx Resubmits New Drug Application For Dsuvia

* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018

BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings

* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEO™ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS

BRIEF-Acelrx Announces Completion Of The Human Factors Study For Dsuvia And Confirms Plans To Resubmit NDA

* ACELRX ANNOUNCES COMPLETION OF THE HUMAN FACTORS STUDY FOR DSUVIA AND CONFIRMS PLANS TO RESUBMIT NDA IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-AcelRx Pharma Q4 Loss Per Share $0.20

* ACELRX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-AcelRX Plans To Resubmit The Dsuvia New Drug Application In Q2

* ACELRX ANNOUNCES RECEIPT OF TYPE A FDA MEETING MINUTES AND PLANS TO RESUBMIT THE DSUVIA NEW DRUG APPLICATION IN Q2 2018

BRIEF-Acelrx Pharmaceuticals posts Q3 loss of $0.28 per share

* Acelrx pharmaceuticals reports third quarter 2017 financial results

AcelRx Pharma shares sink as FDA rejects opioid painkiller

Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.

BRIEF-AcelRx Pharma receives Complete Response Letter from the FDA for Dsuvia™ NDA

* AcelRx Pharmaceuticals receives Complete Response Letter from the FDA for Dsuvia™ NDA

FDA rejects AcelRx Pharma's pain drug

U.S. health regulators did not approve AcelRx Pharmaceuticals Inc's drug Dsuvia in its present form for the management of acute pain in trauma and ambulatory settings, the company said on Thursday.

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up